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Figure S1: Structure and Maldi TOF spectra of dinuclear zinc complexes with phosphorylated amino acids 
and phosphorylated peptides. A. Mass spectrum and structure of Zn2 (EtL1). 2H2BO3. CH3CN (calculated 
mass 881.15; observed mass = 881.9) B. Mass spectrum and structure of Zn2(EtL1) - phosphoserine 
(calculated mass =901.5; observed mass = 898.9). C. Mass spectrum and structure of Zn2 EtL1 complexed 
to 13 amino acid long C terminal phosphorylated Akt peptide, phospho-Akt2-13mer (calculated mass 
=2364.1; observed mass =2361.9). This 13-mer contains the hydrophobic motif of the C-terminus, as well 
as pSer474, and so is the targeted epitope. D. Mass spectrum and structure of Zn2L1-Az4-PEG2-Biotin 
(calculated mass M.2H2O = 1370.2, (M-N2).2H2O = 1342.2; observed mass M.2H2O = 1369, (M-N2).2H2O 
= 1343.8) (PEG = polyethylene glycol). E. Mass spectrum and structure of Zn2L1-Az4-PEG2-Biotin - 
phosphoserine (calculated mass = 1457.22; observed mass =1454.4). F. Mass spectrum and structure of 
Zn2L1-Az4-PEG2-Biotin - phosphotyrosine (calculated mass = 1532.31; observed mass = 1532.39). G. 
Mass spectrum and structure of Zn2L1-Az4-PEG2-Biotin complexed to the peptide substrate for the pSrc 
protein Ac-I-pY-GEF (calculated mass = 2019.86; observed mass =2019.57).  
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Figure S2: Molecular structure of various PCC agents. A. Structure of the monoligand peptide mono-L 
developed against the target epitope. B. 1o ligand is linked to the Zn chelator using the Cu(I) catalyzed click 
reaction. The synthesized molecule 2 binds to the Akt2 fragment containing pS474 to form Complex-2, 
which is used as the target in the biligand screen. C. Molecular structure of the biligand bi-L isolated in the 
screen against the target peptide. 1o ligand (in red) is linked, through Cu catalyzed Alkyne Azide 
Cycloaddition (CuAAC) reaction, to the 2o ligand (in blue). D. An azide is appended at the N terminal of 
the 2 o peptide to synthesize peptide anchor-3N, which is used in screening for 3o ligands that click to the 
N-terminus of the biligand. E. An alkyne is appended to the C terminal of the 1 o peptide to synthesize 
peptide anchor-3C, which is used in screening for 3o ligands that click to the C-terminus of the biligand. 
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Figure S3: Histogram of biligand hit sequences from the in situ click screen. Amino acid frequencies in the 
hit sequences X1X2X3X4X5-D-Pra from X1 to X5 are plotted as histograms. Note that on the basis of the 
frequencies, hnGyf-D-Pra is the consensus sequence.  
 
 
 
Figure S4: Biligand selection on the basis of the efficiency to immunoprecipitate Akt from OVCAR3 cells. 
Biligands with hnGyG - D-Pra (Bi1), hnGyf - D-Pra (Bi2), hnGre -D-Pra (Bi3), hnGai - D-Pra (Bi4) as the 
2o peptide arm are used to immunoprecipitate Akt2 from OVCAR3 cells following the described procedure. 
The best candidate Bi2 is chosen as the biligand bi-L and used in further stages of ligand development.  
That candidate contained the 2o peptide sequence (hnGyf) which, remarkably, is the sequence that best 
reflects the statistic illustrated in the positional histograms of Fig S3.  
 
 
Figure S5: N-terminal triligand selection on the basis of the efficiency to immunoprecipitate Akt from 
OVCAR3 cells. N-terminal triligands synthesized with D-Pra-yyrfG (N-tri1) and D-Pra-ssGry (N-tri2) 
immunoprecipitate Akt2 from OVCAR3 cells. N-tri1 is chosen as the final N terminal triligand N-tL. 
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Figure S6: N-terminal triligand selection on the basis of epitope binding characteristics. Triligand 
candidates from the C terminal screen are tested for binding to the target epitope. The ligand C-t1, with L-
Az4-hdGGf as the third peptide arm, shows good binding and is chosen as the C-terminal triligand C-tL.  
 
 
 
 
ka (1/Ms) kd (1/s) KD (M) 
1.8e5 0.0046 2.5e-8 
 
Figure S7: Sensograms from Surface Plasmon Resonance (SPR) experiment, immobilizing N-tL on SA 
chip and using Akt2 protein as the analyte. A. The data were fit to a simple 1:1 binding model using global 
analysis in Biacore T100 Evaluation software. The equilibrium dissociation constant KD is 25 nM, which is 
in close agreement with the ELISA EC50 value of 19 nM.  
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Figure S8: Coomassie staining of gel from immunoprecipitation by different ligands/ antibody. The 
biotinylated ligands (blank, mono-L, bi-L, N-tL, C-tL) or biotinylated antibody (pS473 mAb) are 
immobilized on streptavidin-agarose beads. The cell lysate (lysate) is directly diluted in the sample buffer 
and ran as a control. The band at 60 kD is for the Akt protein. All the eluted samples (blank to pS473 mAb) 
have similar non-specific protein pulldown.  
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Figure S9: Inhibition of kinase activity of the Akt2 protein when treated with C-tL. The in vitro 
phosphorylation of GSK3α/β substrate by active Akt2 is inhibited when treated with increasing 
concentrations of the C-tL ligand. The solutions are ran on a gel and visualized by treatment with 
pGSK3α/β Ser 21/9 antibody. The western blot image was scanned and the signal corresponding to 
different concentrations of C-tL was quantitated using ImageJ. The density was normalized to the signal 
for no inhibitor (DMSO control) to generate an activity percentage value curve in GraphPad Prism 6.0. An 
EC50 value of 4 µM is obtained from the curve using non-linear regression. 
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Table S1: OBOC peptide libraries used in screens. 
Formula Components Unique  
sequences 
Fraction Screened 
Library A: D-
Pra-XXXXX-
10%M-TG 
X = 18 D amino acids 
except D-Met and D-
Cys 
1,889,568 40% for 1o ligand screen 
80% for 3o ligand screen for N-
tL 
Library B: 
XXXXX -D-
Pra-10%M-TG 
X = 18 D amino acids 
except D-Met and D-
Cys 
1,889,568 40% for 2o ligands 
Library C: L-
Az4- XXXXX-
10%M-TG 
X = 18 D amino acids 
except D-Met and D-
Cys 
1,889,568 80% for 3o ligand screen for C-
tL 
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Table S2:  Hit sequences from biligand (bi-L) screen with 25 nM target peptide. Consensus motifs are 
highlighted.   
X1 X2 X3 X4 X5 D-Pra 
h n G i i D-Pra 
h n G r e D-Pra 
h r y y G D-Pra 
v n r r f D-Pra 
h n G G d D-Pra 
a y p h f D-Pra 
G f r r f D-Pra 
r G f f l D-Pra 
h n G y G D-Pra 
 
Table S3:  Hit sequences from biligand screen with 10 nM target peptide. Consensus motifs are 
highlighted.   
X1 X2 X3 X4 X5 D-Pra 
v y y r h D-Pra 
h n G a i D-Pra 
f h y y y D-Pra 
f y h k h D-Pra 
p f q h f D-Pra 
s h f y t D-Pra 
v h G a a D-Pra 
y h q y G D-Pra 
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Table S4:  Hit sequences from N terminal triligand (N-tL) screen.  
D-Pra X1 X2 X3 X4 X5 
D-Pra k/l* f q f r 
D-Pra r d/n* r f r 
D-Pra y v y r f 
D-Pra s s G r y 
D-Pra y y r f g 
D-Pra s f r r f 
D-Pra s v r f r 
D-Pra i k/l* r r a 
D-Pra r q/t* k/l* w r 
D-Pra r q/t* s r r 
D-Pra r r i y y 
D-Pra r f G r q/t* 
*Alternative amino acid signals from poor resolution of the amino acid standards of the Edman sequencing 
machine.  
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Table S5:  Elimination of peptide binders to antibody from N terminal triligand (N-tL) screen 
D-Pra X1 X2 X3 X4 X5 Color  Probability of being right sequence  
D-Pra k f q f r light 0.25 
D-Pra l f q f r light 0.25 
D-Pra k f t f r light 0.25 
D-Pra l f t f r light 0.25 
D-Pra r d r f r No color 0.5 
D-Pra r n r f r medium 0.5 
D-Pra y v y r f light 1 
D-Pra s s G r y No color 1 
D-Pra r r i y y dark 1 
D-Pra y y r f G No color 1 
D-Pra s f r r f light 1 
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Table S6:  Hit sequences from C terminal triligand (C-tL) screen. Consensus motifs are highlighted.   
L-Az4 X1 X2 X3 X4 X5 
L-Az4 h d G s q 
L-Az4 h d G w w 
L-AZ4 h d G i v 
L-Az4 h d G d w 
L-Az4 h d G G - * 
L-Az4 h d G d r 
L-Az4 h d G G f 
L-Az4 h d G G e 
L-Az4 h d G s f 
L-Az4 h d G q k 
L-Az4 h d G s a 
L-Az4 h d G k f 
L-Az4 r l e a v 
* no signal 
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Supplementary Information Materials and Methods: 
 Materials: Fmoc amino acids were purchased from Anaspec and AAPPTec and used as received.  
TentaGel S-NH2 resin (diameter 90 µm, capacity 0.28 mmol/g) was obtained from Anaspec and utilized for 
OBOC library construction. Biotin NovaTag™ resin, Biotin – PEG NovaTag™ resin, Fmoc – NH - (PEG)2 
- OH (13 atoms) were obtained from EMD Chemicals, Inc. and used for synthesis of biotinylated peptides. 
Amide Sieber resin (capacity 0.3-0.6 mmol/g) purchased from Anaspec was used for synthesis of protected 
peptides. NMP (1-methyl-2 -pyrrolidinone), HATU ((2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylammonium hexafluorophosphate) and DIEA (N,N′-diisopropylethylamine) used in peptide 
synthesis were bought from EMD Chemicals, Inc., ChemPep and Sigma-Aldrich respectively. DMF (N,N′-
dimethylformamide), piperidine, TFA (trifluoroacetic acid, 98% min. titration), and TES (triethylsilane) 
were purchased from Sigma-Aldrich. 5-Azido-pentanoic acid was purchased from Bachem Americas, Inc. 
BCIP (5-Bromo-4-chloro-3-indolyl phosphate) was purchased from Promega.  
  Active Akt2 (with N terminal His6 tag) was purchased from Abcam. Inactive Akt2 (with N 
terminal His6 tag) was purchased from BPS Bioscience. Active Akt1 and Akt3 (with N terminal His6 tag) 
used in ELISA assays were purchased from Sigma Aldrich. Mouse anti biotin antibody-Alkaline 
Phosphatase conjugate used in screens was purchased from Sigma Aldrich. Anti His6 mouse antibody, goat 
anti mouse IgG - Alkaline Phosphatase conjugate used in screens were purchased from Abcam. Mouse anti 
biotin monoclonal antibody- Horse Radish Peroxide conjugate was purchased from Cell Signaling. Anti 
His6 mouse monoclonal antibody and goat anti mouse IgG-Horse Radish Peroxide conjugate were bought 
from Abcam. Anti Akt (pan) rabbit antibody (11E7), and mouse anti-rabbit antibody- Horse Radish 
Peroxide conjugate, used in Western blot and dot blot, were purchased from Cell Signalling. Biotinylated 
mouse PhosphoS473 (pS473) Akt antibody used in immunoprecipitation and PhosphoS473 Akt antibody 
used in western blot was purchased from Cell Signaling. Non-radioactive Akt kinase assay kit was 
purchased from Cell Signaling. 
Synthesis of ethyl 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoate [H(EtL1)]: N, 
N–di(2-picolyl) amine (2.50 g, 12.5 mmol) in ethanol/water/HCl (30 mL/90 mL/0.6 mL of 2M ) was added 
to paraben ( 830 mg, 5 mmol) and paraformaldehyde ( 475 mg, 15.67 mmol). The mixture was heated 
under reflux for 3 days and then allowed to cool to room temperature[1]. Then dichloromethane (300 mL) 
and water (100 mL) was added to the reaction mixture and a liquid phase extraction was done.  The organic 
phase, containing the compound, was washed once with 300 mL of water and dried over anhydrous sodium 
sulphate. A yellowish gummy semisolid was obtained after evaporation of solvent. Column 
chromatography on silica gel with eluents dichloromethane /methanol /ammonium hydroxide afforded light 
yellow semi solid. Calculated mass: [M+H] 588.6 Observed mass: [M+H] 589.29  
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Synthesis of 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid [H(L1)]:  The 
purified semisolid was dissolved in 2 M NaOH in 1:1 ethanol/water solution and stirred at 60 °C for 2 days. 
Then the solution was neutralized by concentrated hydrochloric acid.  The compound was extracted with 
methanol and used in further synthesis. Calculated mass: [M-H] 559.25; Observed mass: [M-H] 559.4.  
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Synthesis of 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoxo dizinc complex 
[Zn2(EtL1)]: 2 equivalents of zinc acetate was dissolved in methanol and added to 1 equivalent of ethyl 
3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoate and stirred overnight at room 
temperature. The solvent was removed under reduced pressure and the solid was purified using a gradient 
of water and acetonitrile and 0.1% TFA on the RP-HPLC (Beckman Coulter System Gold 126 Solvent 
Module and 168 Detector) using a C18 reversed phase semi-preparative column (Phenomenex Luna 10 µm, 
250 × 10 mm).  Calculated mass: 944.48; Observed mass: 945.10.  
 
Synthesis of 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoxo dizinc complex 
[Zn2(L1)-Az4-PEG2-biotin]: D,L-Fmoc-azidolysine was coupled to Biotin – PEG - NovaTag resin  
(coupling efficiency 0.48 mmole/g) following standard Fmoc solid phase synthesis protocol. The Nα-Fmoc 
protecting group was removed by treating with 20% piperidine in NMP. Then 1.5 equivalents of 3,5-
bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid were coupled overnight to the resin. The 
molecule was cleaved off the resin using a cocktail of TFA, TES and double distilled water (95:2.5:2.5), 
precipitated in ice cold ether and lyophilized. The crude solid was used in further synthesis. 2 equivalents 
of zinc acetate was dissolved in methanol and added to 1 equivalent of 3,5-bis((bis(pyridin-2-
ylmethyl)amino)methyl)-4-hydroxybenzoic acid and stirred overnight at room temperature. The solvent 
was removed under reduced pressure and the solid was purified using a gradient of water and acetonitrile 
and 0.1% TFA on the RP-HPLC (Beckman Coulter System Gold 126 Solvent Module and 168 Detector) 
using a C18 reversed phase semi-preparative column (Phenomenex Luna 10 µm, 250 × 10 mm).  
Calculated mass: [M].2H2O 1369.45 Observed mass: [M].2H2O 1369.4 (Figure S1D). 
Verification of binding of dizinc complex to phosphoamino acids and phosphopeptide: 500 µM 
solution of Zn2(EtL1) or Zn2L1-Az4-PEG2-Biotin was made dissolving the HPLC purified solid in 10 mM 
tris borate buffer (TBS) (pH 8). Saturated solutions of pure phosphoserine, phosphotyrosine, Akt peptide C-
terminal motif with 13 amino acids (phospho-Akt2-13mer) and pSrc substrate Ac-I-pY-GEF was made in 
the buffer. The Zn2(EtL1)or Zn2L1-Az4-PEG2-Biotin solution was added to either of the saturated solutions 
in a 1:1 ratio. A fresh matrix was prepared by dissolving 2,4,6-trihydroxyacetophenone (THAP) in 10 mM 
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tris borate buffer (pH 8) with 50% acetonitrile (20 mg/ml). Each solution was mixed in a 1:1 ratio with the 
matrix, and subjected to Maldi TOF in a positive mode. Two controls containing only the Zn2 EtL1 or 
Zn2L1-Az4-PEG2-Biotin solution were also subjected to the Maldi TOF. In the mixed solutions, the peaks 
corresponding to the adduct of the dinuclear Zinc complex to the phosphoamino acid or phosphopeptides 
were observed (Figure S1). 
Solid phase peptide synthesis:  
General protocol: Peptides were synthesized on Rink Amide MBHA, Biotin Novatag, Biotin PEG Novatag 
and Sieber Amide resin either manually or on the Titan 357 Automatic Peptide Synthesizer (AAPPTec, 
Louisville, KY). Amino acid solutions in NMP (2 equivalents), with 2 equivalents of HATU and 6 
equivalents of DIEA were used for the amino acid coupling reaction. For removal of Nα-Fmoc protecting 
groups, a solution of 20% piperidine in DMF was used.  
Acylation: The resin was treated with a solution of anhydrous acetic anhydride and 2,6- lutidine (Sigma) in 
DMF (acetic anhydride: 2,6-lutidine: DMF; 5:6:100), twice for ten minutes at room temperature. The 
excess reagents were removed by five washes with DMF.  
Cleavage of side chain protected peptides: The peptides were synthesized on Sieber Amide resin. The resin 
was treated three times for one minute with 1% TFA/DCM and then washed with DCM. The peptide 
solution was neutralized by adding 2 equivalent DIEA and rotavaped. The semisolid was dissolved in 
filtered DMSO, HPLC grade acetonitrile and double distilled water and purified on the HPLC. 
Cleavage of side chain deprotected peptide: The peptides were synthesized on the Rink Amide MBHA, 
Biotin Novatag or Biotin PEG Novatag resin.  The resin was treated with a TFA cleavage solution (TFA: 
TES: ddH2O; 95:2.5:2.5) for two hours at room temperature.  The cleavage solution was filtered through a 
Gooch filter crucible and added dropwise to an ice cooled solution of diethyl ether.  
HPLC purification of peptides: All the peptides were purified using a gradient of double distilled water and 
HPLC grade acetonitrile and 0.1% TFA on the RP-HPLC (Beckman Coulter System Gold 126 Solvent 
Module and 168 Detector) using a C18 reversed phase semi-preparative column (Phenomenex Luna 10 µm, 
250 × 10 mm).   
Protocol for on bead copper (Cu) catalyzed azide alkyne cycloaddition (CuAAC) click reaction: On bead 
Cu catalyzed click reactions were performed with the azide on bead and the alkyne in solution. The resin 
was treated with 2 equivalents of the relevant alkyne, 1.5 equivalents of CuI (Sigma) and 2.5 equivalents of 
ascorbic acid (Sigma), in a solution of 20% piperidine in DMF. The reaction was performed overnight at 
room temperature. The excess copper was removed from the resin by washing extensively with a Cu 
chelating solution (5% (w/v) sodium diethyl dithiocarbamate, 5% (v/v) DIEA in DMF). 
Peptide library Synthesis:   
Randomized OBOC[2] libraries of hexapeptides were synthesized using the Titan 357 Automated 
Peptide Synthesizer (AAPPTec) on 90 µm polyethylene glycol-grafted polystyrene beads (TentaGel S-
NH2, 0.28 mmol/g, 2.86 x 106 beads/g). All the libraries used unnatural D amino acids including Fmoc-D-
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propargylglycine.  In library C, for azide incorporation, Fmoc-L-azido lysine (Anaspec) was coupled to the 
N termini of the on bead peptides. All the libraries contained 10% D-Methionine at the C terminal, for 
compatibility with Maldi-TOF/ TOF sequencing. The 10% Methionine was incorporated following 
literature protocol[3]. 
Synthesis and characterization of peptide ligands and intermediates: 
Synthesis and characterization of target peptide sequence (phospho-Akt2 peptide) and C terminal 13 
amino acid long phospho-peptide (phospho-Akt2-13mer): The 32mer target peptide sequence 
containing amino acids 450-481 of Akt2, ITPPDRYDSLGLLELDQRTHFPQF(pS)YSASIRE (phospho-
Akt2 peptide), and the 13mer peptide sequence containing amino acids 469-481 of Akt2, 
HFPQF(pS)YSASIRE (phospho-Akt2-13mer), was synthesized on Rink Amide MBHA resin, using the 
Titan 357 peptide synthesizer. Fmoc-Ser(OPO3Bzl)-OH (AaPPTec) was used for the incorporation of 
phosphoserine in the peptide.  It was cleaved by TFA/TES/ddH2O, precipitated in cold ether and purified 
using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Calculated mass: 1645.67; 
observed mass: 1646.55. 
Mass spectrometric analysis of phospho-Akt2-13mer:  ESI –TOF MS: m/z; 823.95 (M+2H) 2+; 549.6 
(M+3H) 3+ 
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Mass spectrometric analysis of phospho-Akt2 peptide: Calculated mass: 3832.0; Observed mass: 
3831.98; ESI –TOF MS: m/z; 767.2 (M+5H) 5+, 959.0 (M+4H) 4+ 
 
Synthesis and characterization of His6 tagged target phospho-Akt2 peptide (His6 - PEG2 – phospho – 
Akt2) and corresponding C terminal peptides from Akt1  (His6 - PEG2 – phospho – Akt1) and Akt3 
(His6 - PEG2 – phospho – Akt3): The target sequence, amino acids 450-481 of Akt2, with pS474, and 
corresponding C terminal sequences of Akt1 (449-480) and Akt3 (448-479) were synthesized on Rink 
Amide MBHA resin, using above mentioned procedure. Fmoc-NH-(PEG)2-OH was then coupled with each 
peptide. Then six successive couplings were done with Fmoc-L-His(Trt)-OH. The peptides were cleaved by 
TFA/TES/ddH2O, precipitated in cold ether and purified using a gradient of water and acetonitrile and 
0.1% TFA on the RP-HPLC.  
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His6 – PEG2 - phospho – Akt2: Calculated mass: 4858.1; Observed mass: 4858.1; ESI –TOF MS: m/z; 
608.18 (M + 8H) 8+, 694.92 (M + 7H) 7+, 810.57 (M+6H) 6+, 972.67 (M+5H) 5+, 1215.35 (M+4H) 4+ 
 
His6 – PEG2 - phospho – Akt1: Calculated mass: Q-TOF: (M+H) 4676.8, (M.4H2O) 4748.8; Observed 
mass: (M+H) 4677.43, (M.4H2O) 4749.59 
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His6 – PEG2 - phospho – Akt3 peptide: Q-TOF: Calculated mass (M+K+H2O) 4953.1, (M+3K) 4965.10; 
Observed mass: (M+K+H2O) 4954.74, (M+3K) 4964.81. 
 
Synthesis and characterization of mono-L: Fmoc-NH-PEG2-OH was coupled using standard Fmoc 
protocol on Biotin Novatag resin. 1.5 equivalents of D, L-Fmoc-azidolysine were coupled on the resin 
followed by acylation. On bead Cu catalyzed click reaction was carried out following described protocol 
using 2 equivalents of Fmoc-D-Pra-OtBu. After washes with the copper chelating solution the peptide was 
acylated. The resultant molecule S1 (figure S10) was cleaved off the resin using TFA cleavage solution. 
The crude solid was used in further synthesis. 
The peptide wkvkl was made on Rink Amide MBHA resin (Anaspec) following standard Fmoc 
SPPS synthesis protocol. 1.5 equivalents of S1 were then coupled to the peptide.  After TFA cleavage the 
ligand mono-L was purified using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. 
Calculated mass:  1494.8.  Observed mass: 1494.6  
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Mass spectrometric analysis of mono-L: 
 ESI –TOF MS: m/z; 498.95 (M + 3H) 3+, 747.92 (M + 2H) 2+ 
 
Figure S10: Synthesis of mono-L 
 
Synthesis and characterization of 2: Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol on 
Biotin Novatag resin. 1.5 equivalent of D, L-Fmoc-azidolysine was coupled on the resin followed by 
coupling of 1.5 equivalent of 3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)-4-hydroxybenzoic acid. The 
resin was then subjected to on bead Cu catalyzed click reaction with Fmoc - D-Pra-OtBu (Fmoc - D-
propargylglycine tertiary butyl ester). The excess copper was removed by washing with the copper 
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chelating solution. 5-Azido-pentanoic acid was then coupled. The resulting peptide S2 (Figure S11) was 
TFA cleaved and lyophilized. The crude was used in further synthesis. The peptide wkvkl was made on 
Rink Amide MBHA resin following standard Fmoc SPPS synthesis protocol. 1 equivalent of peptide S2 
was then coupled to the peptide. The peptide was cleaved off using TFA cleavage solution. 2 equivalents of 
zinc acetate were dissolved in methanol and added to 1 equivalent of crude peptide and stirred overnight at 
room temperature. The solvent was removed under reduced pressure and the solid was purified using a 
gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: [M+Na] 2291, 
[M+Na.TFA] 2404 Mass observed: [M+Na] 2289.98, [M+Na.TFA] 2403.95  
Mass spectrometric analysis of 2:  
Mass calculated: [M+Na]+ 2291, [M+Na.TFA] +1 2404 Mass observed: [M+Na]+ 2289.98, [M+Na.TFA] +1 
2403.95 
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Figure S11:  Synthesis of intermediate S2 and 2 
 
Synthesis and characterization of bi-L: Fmoc-NH-PEG2-OH was coupled using standard Fmoc protocol 
on Biotin Novatag resin. 1.5 equivalent of D,L-Fmoc-azidolysine was coupled on the resin followed by 
acylation of the amine terminal. On bead click reaction was carried out with 2 equivalents of Fmoc-D-Pra-
OtBu. After washes with copper removing solution, 5-azido-pentanoic acid was coupled. After TFA 
cleavage the resultant molecule S3 (figure S12) was lyophilized and the crude solid was used in further 
synthesis. The peptide wkvkl was made on Rink Amide MBHA resin (Anaspec) following standard Fmoc 
SPPS synthesis protocol. 1 equivalent of S3 was then coupled to the peptide on bead. Fmoc-D-Pra-OtBu 
was then clicked to the azido functionality on bead. After washes with the copper chelating solution, the 
peptide was further extended to hngyf on the N terminal using standard Fmoc SPPS synthesis. After TFA 
cleavage the biligand was purified using a gradient of water and acetonitrile and 0.1% TFA on the RP-
HPLC. Mass calculated: 2309.7 Mass observed: 2309.4  
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Mass spectrometric analysis of bi-L: ESI –TOF MS: m/z; 770.44 (M + 3H) 3+, 578.33 (M + 4H) 4+ 
 
Figure S12:  Synthesis of compound S3. S3 is used in the synthesis of the bi-L, Anchor-3C and C– tL 
 
Synthesis and characterization of Anchor-3N:  Fmoc-NH-PEG2-OH was coupled using standard Fmoc 
proteocol on Biotin Novatag resin. 1.5 equivalent of D, L-Fmoc-azidolysine was coupled on the resin 
followed by acylation using acetic anhydride and 2,6-lutidine in DMF. On bead click reaction with Fmoc-
D-Pra-OtBu was carried out. After washes with copper chelating solution Fmoc-L-azidolysine was coupled. 
Following removal of the Fmoc protecting group, the amine terminal was acylated. After TFA cleavage the 
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resultant molecule S4 (figure S13) was lyophilized and the crude solid was used in further synthesis. The 
peptide wkvkl was made on Rink Amide MBHA resin. 1.5 equivalents of S4 were then coupled to the 
peptide. On bead click reaction was carried out with two equivalents of Fmoc-D-Pra-OtBu. After washes 
with copper removing solution, the peptide was further extended to hngyf on the N terminal using standard 
Fmoc SPPS synthesis. Fmoc-L-azidolysine was then coupled, followed by acylation of the amine terminal. 
After TFA cleavage Anchor-3N was purified using a gradient of water and acetonitrile and 0.1% TFA on 
the RP-HPLC. Mass calculated: 2534.9 Mass observed: 2534.6  
Mass spectrometric analysis of Anchor-3N:  ESI –TOF MS: m/z; 634.60 (M + 4H) 4+ 
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Figure S13:  Synthesis of intermediate compound S4 for anchor-3N and N-tL 
 
Synthesis and characterization of Anchor-3C: The peptide NH2-wkvkk(Alloc) was made on Rink Amide 
MBHA resin following standard Fmoc SPPS synthesis protocol. 1 equivalent of S3 (figure S12) was then 
coupled to the resin.  On bead click reaction was carried out overnight using 1.5 equivalents of Fmoc-D-
Pra-OtBu. After washes with the copper chelating solution, the peptide was further extended to hngyf on 
the N terminal using standard Fmoc SPPS synthesis. Then it was acylated again. The alloc side chain of 
Fmoc-D-lysine(Alloc)-OH  was  deprotected using standard alloc deprotection technique[4]. Then 4-
pentynoic acid was coupled.  After TFA cleavage, Anchor-3C was purified using a gradient of water and 
acetonitrile and 0.1% TFA on the RP-HPLC. Mass calculated: 2446.8; Mass observed: 2446.5 
Mass spectrometric analysis of Anchor-3C: ESI –TOF MS: m/z; 816.11 (M + 3H) 3+, 612.59 (M + 4H) 4+ 
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Synthesis and characterization of N-tL: Side chain protected version of Ac-D-Pra-yyrfG-CONH2 was 
made on Amide Sieber resin. The protected peptide was cleaved off using 1% TFA in DCM and purified 
using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. Anchor-3N was made on resin 
as described and then acylated using standard acylation method. On bead click reaction was carried out for 
the bead bound Anchor-3N with 2 equivalents of side chain protected purified peptide Ac-yyrfG-CONH2. 
The resin was washed with copper chelating solution. The peptide was cleaved off the resin with the TFA 
cleavage solution and purified using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. 
Mass calculated: 3417.9 Mass observed: 3417.5 
Mass spectrometric analysis of N-tL: ESI –TOF MS: m/z; 684.56 (M+5H) 5+, 855.20 (M + 4H) 4+, 
1140.26 (M + 3H) 3+ 
 
Synthesis of D-Lys (pentyne) amide: Boc-D-Lys(Fmoc)-OH was coupled with rink amide resin. Then 4-
pentynoic acid was coupled with it, after standard piperidine deprotection. The dried resin was cleaved with 
TFA cocktail and purified using a gradient of water and acetonitrile and 0.1% TFA on the prep-HPLC. 
Mass calculated: (M+H) 225 Mass observed: 226 
Synthesis and characterization of C-tL: Ac-L-Az4-hdGGf (Az4 = azidolysine) was made on Rink Amide 
MBHA resin. On bead click reaction of the peptide on resin with D-Lys(pentyne) amide was carried out 
overnight at room temperature with 2 equivalents of D-Lys(pentyne) amide. The resin was washed with the 
copper chelating solution and further extended to wkvk on the N terminal using standard Fmoc SPPS 
synthesis. Then, 1.5 equivalent of S3 was coupled to the peptide. An on bead click reaction was carried out 
with Fmoc-D-Pra -OtBu. After washes with copper chelating solution, the peptide was further extended to 
hngyf on the N terminal using standard Fmoc SPPS synthesis. The dried resin was cleaved with TFA 
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cleavage solution and purified using a gradient of water and acetonitrile and 0.1% TFA on the RP-HPLC. 
Mass calculated: 3199.65; Mass observed: 3198.44.  
Mass spectrometric analysis of C-tL: ESI –TOF MS: m/z; 640.76 (M+5H) 5+, 800.45 (M+4H) 4+ 
 
Screening with One Bead One Compound (OBOC) peptide library: 
Screen for mono-L:   
50 nM solution of the Akt2 peptide was made by diluting 0.5mg/ml DMSO stock in 25 mM tris 
chloride, 150 mM NaCl, 2 mM KCl, pH 8) (TBS). 100 µM solution of the Zn2L-Az4-PEG2-Biotin was 
added to the 50 nM solution of the phospho-Akt2 peptide and shaken overnight at room temperature. 
Before the addition to the OBOC library, Bovine Serum Albumin (BSA) and Tween 20 was added to the 
solution to make the final concentrations 0.1 % BSA and 0.05% tween 20 in the buffer. 250 mgs of library 
A (D-Pra-XXXXX-10%M-TG, supplementary table S1) were used in the screen. The beads were 
equilibrated in 0.1% BSA, 0.05% Tween 20/TBS (binding buffer) by shaking for 8 hours. The Zn2L-Az4-
PEG2-Biotin –Akt2 peptide solution was added to the swelled beads and shaken overnight at room 
temperature. The beads were washed three times with the binding buffer. A 1:10,000 dilution of mouse anti 
biotin monoclonal antibody-Alkaline Phosphatase conjugate (Sigma) in binding buffer was added to the 
beads. The beads were then washed thrice with binding buffer, thrice with TBST (0.05% tween 20/TBS) 
and thrice with TBS. 
  A BCIP solution was freshly prepared by adding 33 ul of BCIP (50 mg/ml) stock solution in 10 ml 
of Alkaline Phosphatase buffer (100 mM Tris-HCl, pH 9.0, 150 mM NaCl, 1 mM MgCl2) (Promega). The 
beads were washed once with the Alkaline Phosphatase buffer, and then treated with the fresh BCIP 
solution. The hit beads turned turquoise blue due to a colorimetric reaction of Alkaline Phosphatase with 
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BCIP.  The reaction was quenched after one hour with 0.1 N HCl. The hit beads were picked with a pipette 
tip and transferred to an eppendorf tube. The turquoise color of the hit beads was removed by washing with 
DMF. The proteins on the beads were stripped by washes with 7.5 M guanidium hydrochloride pH 2.0 
solution. Then beads were then equilibrated in buffer. The screen was repeated on this small set of beads, 
this time using a preincubated mixture of 2.5 mM biotin and 1:10,000 dilution of a mouse anti biotin 
monoclonal-Alkaline Phosphatase conjugate (Sigma) as the secondary antibody. On addition of the BCIP, 
the true hits, due to competition with biotin, remain clear. The clear beads were manually picked, washed 
with guanidium hydrochloride and water, and sequenced using the Edman Peptide Sequencer. 
Screen for bi-L: 
Prescreen: 2 batches of 135 mg of library B (XXXXX-D-Pra- 10% M- TG, Supplementary table S1) 
were washed in water, and swelled overnight in binding buffer (25 mM Tris-Cl (pH = 7.7), 150 mM NaCl, 
2 mM KCl, 0.1% (v/v) Tween-20, and 0 . 1  % BSA). 20 µM and 50 µM solutions of 2 (figure S2B) was 
added to the beads and shaken for 10 hours at room temperature. The beads were washed thrice, for fifteen 
minutes each, with the binding buffer.  A 1:10,000 dilution of mouse anti biotin antibody-Alkaline 
Phosphatase conjugate (Sigma) in binding buffer was added to the beads. The beads were washed three 
times, for fifteen minutes each, with wash buffer 1 (25 mM Tris-Cl (pH = 7.7), 150 mM NaCl, 2 mM KCl, 
0.1% (v/v) Tween-20), followed by three fifteen minute washes with wash buffer 2 (25 mM Tris-Cl (pH = 
7.7), 150 mM NaCl, 2 mM KCl). The beads were then developed in BCIP solution for 35 minutes and 
quenched with 0.1 N HCl.  The blue hit beads, which were background binders to the mono-L-Zn chelator 
or the detection antibody were picked up manually. The clear beads were stringently washed with DMF, 
7.5 mM guanidium hydrochloride, pH 2.0, and double distilled water.  
Product screen: The washed beads from each prescreen were dried and swelled overnight in binding in 8 
ml fritted polypropylene solid-phase synthesis tubes.  In two separate eppendorf tubes, 20 µM and 50 µM 
solution of 2 was incubated overnight at room temperature with 10 nM and 25 nM phospho-Akt2 peptide 
solution respectively, in binding buffer. 4 mL of each of the two solutions were added to a precleared 
swelled bead batch and the tubes were shaken at room temperature for ten hours. The beads were washed 
three times, for fifteen minutes each, with wash buffer 1 followed by three fifteen minute washes with 
wash buffer 2. The beads are then developed in BCIP solution for thirty-five minutes and quenched with 
0.1 N HCl. The blue hit beads were picked up manually, stringently washed with DMF, guanidium 
hydrochloride and water, and sequenced on the Edman Sequencer.  The sequences from the biligand 
screen are given in tables S2 and S3. 
Selection of final biligand bi-L: Several biligand candidates were synthesized by Cu catalyzed click 
reaction which contained either a direct hit sequence (hnGyG—D-Pra, hnGre-D-Pra, hnGai - D-Pra, hnGii 
– D-Pra, hnGGd – D-Pra) or the consensus sequence from the amino acid histograms (hnGyf - D-Pra from 
figure S3) as the 2° peptide. Biligands with the second peptide arm as hnGyG - D-Pra (Bi1), hnGyf - D-
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Pra (Bi2), hnGre -D-Pra (Bi3), hnGai - D-Pra (Bi4), hnGii – D-Pra (Bi5), hnGGd – D-Pra (Bi6) were 
tested for immunoprecipitation of Akt from OVCAR3 cells. Eluents from the immunoprecipitation from 
Bi1, Bi2, Bi3 and Bi4 were run on a western blot and eluents from the immunoprecipitation from Bi5 and 
Bi6 are blotted directly on nitrocellulose and treated with anti-Akt pan antibody. The western blot was 
given in figure S4 and the dot blot did not show any Akt pulldown. On the basis of the pulldown efficiency 
Bi2, which has hnGyf - D-Pra as the 2° peptide arm, was chosen as the final biligand candidate.  
Screen for N-tL: 
Prescreen: 500 mg of library A (D-Pra-XXXXX-10%M- TG, Supplementary table S1) were swelled in 
binding buffer (25 mM Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM MgCl2, 0.1% BSA, 0.05% Tween-20) 
overnight.  The beads were incubated with 25 µM solution of anchor-3N in binding buffer for two hours at 
4°C. The beads were washed three times for five minutes each, with binding buffer. The beads were treated 
for two hours with 7.5 M Guanidium chloride (pH = 2) and washed ten times with double distilled water. 
The beads were equilibrated in binding buffer.  A 1:10,000 dilution of mouse anti biotin antibody-Alkaline 
phosphatase conjugate (Sigma) in binding buffer was added to the beads. The beads were washed three 
times, for five minutes each, with wash buffer 3  (25 mM Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM 
MgCl2,  0 . 0 5 % (v/v) Tween-20), followed by three five minute washes with wash buffer 4 (25 mM 
Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM MgCl2). The beads were then developed in BCIP solution for 
thirty minutes and quenched with 0.1 N HCl.  The blue hit beads, which were background binders to the 
anchor-3N or the antibody were separated from the rest of the beads.  The clear beads were stringently 
washed with DMF, guanidium hydrochloride and water and used in the product screen. 
Product screen: The clear beads from the prescreen were swelled overnight in binding buffer (25 mM Tris-
Cl (pH = 7.5, 150 mM NaCl, 10 mM MgCl2, 0.05% (v/v) Tween-20, and 0 . 1% BSA). 25 µM solution 
of anchor-3N was incubated for thirty minutes at 4°C with 50 nM Akt2 in binding buffer. The solution was 
added to the beads and shaken at 4°C for two hours. The beads were washed three times, for five minutes 
each, with the binding buffer. The beads were treated for two hours with 7.5 mM guanidium chloride (pH = 
2) and washed ten times with double distilled water. The beads were re-equilibrated in binding buffer.  A 
1:10,000 dilution of mouse anti biotin antibody-alkaline phosphatase conjugate (Sigma) in binding buffer 
was added to the beads. The beads were washed three times, for five minutes each, with wash buffer 3 
followed by three five minutes washes with wash buffer 4. The beads were then developed in BCIP 
solution for thirty minutes and quenched with 0.1 N HCl. The blue hit beads were picked up manually, 
stringently washed with DMF, guanidium hydrochloride and water, and used in the target screen. 
Target screen: The washed hit beads from the product screen were swelled overnight in binding buffer (25 
mM Tris-Cl (pH = 7.5, 150 mM NaCl, 10 mM MgCl2, 0.05% (v/v) Tween-20, and 0 . 1% BSA). 50 nM 
Akt2 protein, preincubated with 73.5 µM anchor-3N for thirty minutes at 4°C, was added to the swelled 
beads and the beads were shaken for ninety minutes at 4°C. The beads were washed three times, for five 
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minutes each, with the binding buffer.  A 1:1000 dilution of mouse anti His6 antibody (Abcam) in binding 
buffer was added to the beads and incubated for an hour with shaking at 4°C. Following three five minute 
washes with the binding buffer, a 1:10,000 diluted solution of anti mouse –alkaline phosphatase (Sigma) 
was added and the shaken for one hour at 4°C. The beads were washed three times for five minutes each 
with wash buffer 3, followed by three five minute washes with wash buffer 4. The beads were then 
developed in BCIP solution for thirty minutes and quenched with 0.1 N HCl. The blue hit beads were 
picked up manually, stringently washed with DMF, guanidium hydrochloride and water, and sequenced on 
the Edman Sequencer. The sequences obtained are listed in Table S4. Because of poor resolution of amino 
acid standards in the Edman Peptide Sequencer during that time, some peptides were assigned to have 
either one of two amino acids in some positions. 
Elimination of peptides binding to anti-Akt antibody: Since a preclear screen was not performed against the 
mouse-Anti His6 antibody and the anti-mouse-alkaline phosphatase antibody, to eliminate peptide binders 
to the antibodies, all the dark colored peptide hits obtained in the earlier target screen were synthesized on 
Tentagel – S - NH2 resin. 10 beads of each sequence was taken in spinnex tubes, equilibrated in binding 
buffer, and then treated with a 1:1000 diluted solution of mouse anti His6 antibody (Abcam) for an hour at 
4°C. Following three five minute washes with the binding buffer, a 1:10,000 diluted solution of anti mouse 
–alkaline phosphatase was added and the shaken for one hour at 4°C. The beads were washed three times 
for five minutes each with wash buffer 3, followed by three five minute washes with wash buffer 4. The 
beads were then developed in BCIP solution for thirty minutes and quenched with 0.1 N HCl. The color 
intensity of the different sequences are recorded in Table S5, along with the probability that the sequence is 
a binder to the protein and not a background binder (clear beads).  The probability arises from the poor 
resolution of certain amino acid standards in the Edman sequencer during sequencing the hits from the N 
terminal triligand target screen. 
Selection of final N terminal triligand N-tL: Two sequences were observed (table S5) which were not 
background binders (remain clear in the antibody binder elimination screen) and which had the full 
probability of being the right sequence. These two 3° peptides, D-Pra-yyrfG and D-Pra-ssGry, were clicked 
to anchor-3N by CuAAC reaction and tested as triligand candidates (N-tri1 and N-tri2 respectively). 
These were used to immunoprecipitate Akt2 from OVCAR3 cells (figure S5). The first triligand candidate 
N-tri1 being more efficient was chosen as the final N terminal triligand N-tL. 
Screen for C-tL: 
Prescreen: 500 mgs of library C (H2N-Az4-XXXXX-10%M-TG, table S1) was swelled in binding buffer 
overnight.  The beads were incubated with 100 µM solution of anchor-3C in binding buffer for two hours 
at 4°C. The protocol for the prescreen for N-tL screen was followed. The blue hit beads, which were 
background binders to the anchor-3C or the detection antibody were separated from the rest of the beads. 
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The clear beads were stringently washed with DMF, guanidium hydrochloride and water and used in the 
product screen that followed. 
Product screen: The washed beads from the prescreen were swelled overnight in binding buffer 100 uM 
solution of anchor-3C was incubated for thirty minutes at 4°C with 50 nM Akt2 in binding buffer. The 
solution was added to the beads and shaken at 4°C for two hours. The protocol for the N-tL product screen 
was followed. The blue hit beads were picked up manually, stringently washed with DMF, guanidium 
hydrochloride and water, and sequenced on the Edman Sequencer. The sequences are recorded in Table S6. 
Selection of the final C terminal triligand C-tL: Four triligand candidates were synthesized with L-Az4-
hdGGf (C-t1), L-Az4-hdGsf (C-t2), L-Az4-hdGww (C-t3), L-Az4-hdGkf (C-t4) as the 3° peptide arm. 
Binding of the candidates to the target peptide epitope was determined in an ELISA assay (Figure S6) and 
the ligand C-t1 emerged as the best binder. C-t1 was chosen as the C terminal triligand C-tL. 
Epitope/ Protein Selectivity Assay:   
1.25 µM biotinylated ligand was prepared by diluting the 1 mM stock in binding buffer (25 mM 
tris chloride, pH= 7.4, 150 mM NaCl, 0.1% BSA, 0.05% Tween 20).  The prepared ligand solution or 0.125 
% DMSO in buffer (buffer control) was immobilized on a High Capacity Streptavidin 96 well plate 
(Thermo Scientific). After washing away the excess ligand, the plate was blocked overnight with 1% BSA 
/25 mM tris chloride, pH= 7.4/ 150 mM NaCl, 0.05% Tween 20. 2.5 µM solutions of the His6 tagged target 
phosphopeptide epitope Akt2 amino acids 450 – 481, His6 tagged Akt1 amino acids 449-480, His6 tagged 
Akt3 amino acids 448-479 were added to each of the wells.  Following three washes with the binding 
buffer, the plate was treated for an hour with a 1:1000 dilution of anti His6 mouse monoclonal antibody. A 
1:10,000 dilution of goat anti mouse antibody-Horse Radish Peroxide conjugate in binding buffer was 
added to the wells. The plates were washed four times, five minutes each, with 0.05% Tween 20/ TBS (25 
mM tris chloride, pH= 7.5, 150 mM NaCl) and once with TBS (25 mM tris chloride, pH= 7.5, 150 mM 
NaCl). Color was developed by adding TMB substrate (KPL) to each well. The reaction was quenched 
with 0.5 M H2SO4. The A450 measured on a 96-well plate reader. The Net A450 was obtained by 
subtracting the absorbance value for the blank control (no immobilized ligand) from each of the triplicate 
values obtained for the ligand-epitope interaction. 
The selectivity assay with full length His6 tagged Akt1, Akt2 and Akt3 was performed following 
the same protocol, using 25 nM protein instead of 2.5 µM His6 tagged peptide epitope.  
Measurement of binding affinity of N-tL by Surface Plasmon Resonance:  
A Biacore T100 mach ine  was used for SPR experiments. A Streptavidin Chip  (Series S, G.E. 
Healthcare) was conditioned as per manufacturer’s recommendation. A  s t o c k  o f  1  m M  
biotinylated ligand was diluted into HBSP+ Buffer (G.E. Healthcare) to a final concentration of 100 nM 
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and ~150 RU was immobilized on the chip. Serial dilutions of the Akt2 protein were made in HBSP+ 
buffer for the experiment with the immobilized N-tL. The solution was flowed over the chip at 50 µL/min. 
Binding and dissociation were carried out at 10°C with a contact time of 350 sec, a dissociation time of 
390 sec, and a stabilization time of 200 sec, with buffer blanks between each concentration.  The response 
was double corrected, using an unmodified reference flow cell and the response for the 0 concentration of 
Akt2 on the sample flow cell.  The data was fitted to the kinetic Langmuir 1:1 binding model 
using the Biacore Evaluation software for T100 to calculate the dissociation constant.  
OVCAR3 lysate pulldown assay:   
OVCAR3 cells (ATCC) were grown in RPMI-1640 media containing 20% fetal bovine serum.  
Passage three cells were grown to ~ 80% confluence. Cells were lysed with lysis buffer (10 mM Tris-Cl 
(pH = 7.5), 100 mM NaCl, 1% (v/v) Triton X-100, 0.1% SDS (w/v), 0.5% deoxycholate, 1 mM DTT, 1 
mM EDTA, 1X PhosStop phosphatase inhibitors (Roche), 1X Complete protease inhibitors (Roche)) and 
the amount of protein measured using BCA Protein Assay Kit (Pierce Biotechnologies, Inc). Streptavidin-
agarose resin solution (EMD) was swelled in TBST (25 mM tris chloride, pH= 7.5, 150 mM NaCl, 
0.05% Tween-20). Each of the biotinylated ligands was immobilized on the Streptavidin-agarose resin by 
adding 7.2 µL of 1 mM ligand stock (DMSO) to 10 µL of the swelled streptavidin-agarose resin. For 
the blank control, the resin was treated with 7.2 µL of 1 mM biotinylated acyl glycine. Biotinylated pS473 
antibody (Cell Signaling) was added in a 1:200 ratio as per vendor’s suggestion. After shaking overnight 
at 4°C, 50 µM D-biotin was added to the resin to block any remaining sites. The resin was washed with 
TBST five times, for fifteen minutes each. The resin was then swelled in binding buffer for two hours. To 
each of the immobilized ligands, 200 µL OVCAR3 cell lysate (1.9 mg/ml) was added. The tubes were 
shaken at 4°C for 18 hours. The beads were ex t ens ive ly  washed, three times for fifteen minutes in 
binding buffer, three times (fifteen minutes) in TBST, and three times (fifteen minutes) in TBS to remove 
unbound proteins. The resin bound proteins were eluted by adding 4 0 µL of 2X SDS-PAGE 
s a m p l e  loading buffer (BioRad) and heating at 95°C for five minutes. A 1:10 diluted sample of 
lysate in sample loading buffer was prepared by mixing 1  µl of the sample with 9 µl sample loading buffer 
and denaturing the sample by heating at 95°C for five minutes. 10 µL of each sample was loaded on a 
12% SDS-PAGE gels (BioRad) and run for 80 minutes at 110 volts. Three identical gels were loaded and 
run at the same time. One gel was used for Coomassie staining with Coomassie Fluor Orange Protein Gel 
Stain (Molecular Probes) following the manufacturer’s protocol. The two other gels were transferred to 
nitrocellulose membranes by the semidry transfer method, blocked for two hours at 4°C with 5% non-fat 
milk, and treated overnight at 4°C with a 1:1000 dilution of pan-Akt rabbit monoclonal antibody (Cell 
Signaling Technology) and a 1:1000 dilution of pS473 Akt rabbit monoclonal antibody (Cell Signaling 
Technology), respectively, in 0.5% non-fat milk. The membranes were washed and treated for an hour with 
a 1:10,000 dilution of monoclonal mouse anti-rabbit- HRP secondary antibody (Cell Signaling 
Technology) in 0.5% milk. After five washes of five minutes each with TBST and one wash of five 
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minutes with TBS, the blots were developed with West Dura ECL substrate (Thermo Scientific) and 
imaged on film. 
Non-radioactive kinase assay to evaluate effect of ligands on Akt2 kinase activity: 
The non–radioactive kinase assay kit for Akt2 was purchased from Cell Signaling. Ligand 
solutions were made in DMSO. Kinase reactions were set up in 1X kinase buffer (25 mM trisHCl (pH 7.5), 
10 mM MgCl2, 0.01% Triton-X, 1X Complete protease inhibitor (Roche), 1X Phosstop phosphatase 
inhibitor (Roche)), each 25 µL reaction mixture containing 400 ng Akt2, 400 ng GST-GSK-3α/β fusion 
protein, 500 mM ATP and 0.5 µL of peptide solutions in DMSO or DMSO only. Reactions were allowed to 
proceed for 30 minutes at 30°C. A reaction mixture was also prepared using a 1:2.5 dilution of anti pS473 
antibody (Cell Signaling) in the kinase buffer instead of the peptide ligand or DMSO. The react ions 
were quenched by adding 12.5 µL of 2X SDS sample loading buffer and heating at 95°C for  f ive 
minutes .  10 µL from each sample was loaded on an any kD SDS gel (Biorad) and run for an hour at 110 
volts. Following semidry transfer of the gel to a nitrocellulose membrane, the membrane was blocked in 
5% nonfat milk/TBST for an hour at 4°C, and treated overnight at 4°C with a 1:200 dilution of Phospho 
GSK-3α/β Ser (21/9) rabbit antibody (Cell Signaling) in 0.5% milk/TBST. Following washes, the 
membrane was treated with a 1:2000 dilution of mouse anti-rabbit –HRP antibody for an hour at 4°C. After 
four five minute washes with TBST, and one five minute wash with TBS, the membrane was treated with 
West Dura ECL substrate (Thermo Scientific) and imaged on film.  
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